AR031834A1 - Una composicion farmaceutica adecuada para su administracion por via oral, procedimientos para prepararla, una formulacion oral que la comprende, uso de un derivado de la camptotecina, un glicerido poliglicolizado y de un excipiente farmaceuticamente aceptable seleccionado entre lecitina, un fosfoli - Google Patents
Una composicion farmaceutica adecuada para su administracion por via oral, procedimientos para prepararla, una formulacion oral que la comprende, uso de un derivado de la camptotecina, un glicerido poliglicolizado y de un excipiente farmaceuticamente aceptable seleccionado entre lecitina, un fosfoliInfo
- Publication number
- AR031834A1 AR031834A1 ARP000105495A ARP000105495A AR031834A1 AR 031834 A1 AR031834 A1 AR 031834A1 AR P000105495 A ARP000105495 A AR P000105495A AR P000105495 A ARP000105495 A AR P000105495A AR 031834 A1 AR031834 A1 AR 031834A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- polyglycolized
- procedures
- oral
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 3
- 239000002775 capsule Substances 0.000 abstract 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 125000005456 glyceride group Chemical group 0.000 abstract 2
- 229940067606 lecithin Drugs 0.000 abstract 2
- 235000010445 lecithin Nutrition 0.000 abstract 2
- 239000000787 lecithin Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000003679 cervix uteri Anatomy 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 210000001635 urinary tract Anatomy 0.000 abstract 1
- 210000004291 uterus Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composicion farmacéutica adecuada para su administracion por vía oral que comprende un derivado de camptotecina, una matriz de vehículo farmacéuticamente aceptable que es un glicérido poliglicolizado y, por lo menos, un excipiente farmacéuticamente aceptable seleccionado entre una lecitina, un fosfolípido, un aceite farmacéuticamente aceptable, un polietilenglicol y un mono-, di- o tri-glicérido saturado o insaturado. Procedimientos para preparar la composicion, una formulacion oral que comprende a la composicion farmacéutica y el uso de un derivado de la camptotecina, de un glicérido poliglicolizado y de un excipiente farmacéuticamente aceptable seleccionado entre una lecitina, un fosfolípido, un aceite farmacéuticamente aceptable, un polietilenglicol o un mono-, di- o triglicérido. La composicion farmacéutica puede administrarse a un mamífero, e inclusive a un ser humano, que pueda necesitar los efectos beneficiosos de la formulacion de un derivado de camptotecina. En consecuencia, las cápsulas pueden ser utilizadas para efectuar el tratamiento de una gran variedad de tipos de cáncer diferentes entre los que se incluyen, de manera no taxativa, los cánceres humanos de colon, mamas, pulmon, prostata, melanoma, páncreas, hígado, estomago, cerebro, rinon, utero, cuello del utero, ovarios y tracto urinario. Preferentemente, en los casos en los que la cápsula comprende CPT-11, esta cápsula se puede utilizar para el tratamiento del cáncer de colon y, en particular, del cáncer colorrectal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9925127.4A GB9925127D0 (en) | 1999-10-22 | 1999-10-22 | Oral formulations for anti-tumor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031834A1 true AR031834A1 (es) | 2003-10-08 |
Family
ID=10863264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000105495A AR031834A1 (es) | 1999-10-22 | 2000-10-19 | Una composicion farmaceutica adecuada para su administracion por via oral, procedimientos para prepararla, una formulacion oral que la comprende, uso de un derivado de la camptotecina, un glicerido poliglicolizado y de un excipiente farmaceuticamente aceptable seleccionado entre lecitina, un fosfoli |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7201913B1 (es) |
| EP (1) | EP1223936A1 (es) |
| JP (1) | JP2003512430A (es) |
| KR (1) | KR100838097B1 (es) |
| CN (1) | CN1198616C (es) |
| AR (1) | AR031834A1 (es) |
| AU (1) | AU784201B2 (es) |
| BR (1) | BR0014902A (es) |
| CA (1) | CA2387648A1 (es) |
| CO (1) | CO5251471A1 (es) |
| CZ (1) | CZ20021372A3 (es) |
| EA (1) | EA008284B1 (es) |
| GB (1) | GB9925127D0 (es) |
| HK (1) | HK1048253B (es) |
| HU (1) | HUP0202850A3 (es) |
| IL (2) | IL149044A0 (es) |
| MX (1) | MXPA02003904A (es) |
| MY (1) | MY138106A (es) |
| NO (1) | NO322782B1 (es) |
| NZ (1) | NZ518398A (es) |
| PE (1) | PE20010809A1 (es) |
| PL (1) | PL356236A1 (es) |
| SK (1) | SK5102002A3 (es) |
| TW (1) | TWI233355B (es) |
| WO (1) | WO2001030351A1 (es) |
| ZA (1) | ZA200203042B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE200200471A (et) * | 2000-02-28 | 2003-12-15 | Aventis Pharma S.A. | Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks |
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| ITRM20030074A1 (it) * | 2003-02-21 | 2004-08-22 | Pharmacia Italia Spa | Formulazioni semisolide a rilascio immediato intese |
| US7871632B2 (en) | 2004-07-12 | 2011-01-18 | Adventrx Pharmaceuticals, Inc. | Compositions for delivering highly water soluble drugs |
| GT200500310A (es) | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
| SA06270147B1 (ar) | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
| US20070053869A1 (en) * | 2005-09-02 | 2007-03-08 | Yuichi Sugiyama | Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| WO2008090732A1 (ja) | 2007-01-26 | 2008-07-31 | Pola Pharma Inc. | 医薬組成物 |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| CN101809024A (zh) * | 2007-07-16 | 2010-08-18 | 铂雅制药公司 | 吡铂的口服制剂 |
| CN102006875A (zh) * | 2008-02-08 | 2011-04-06 | 帕纳德制药公司 | 吡铂和贝伐单抗治疗结直肠癌的用途 |
| HUP0900614A2 (en) * | 2009-09-29 | 2011-05-30 | Mate Dr Hidvegi | Preparation comprising dehydrated, fermented material with amorphous crystaline structure and process for its production |
| US20120322752A1 (en) * | 2009-12-08 | 2012-12-20 | Sung Kyun Lee | SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL |
| WO2014123899A1 (en) | 2013-02-05 | 2014-08-14 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| JP6704345B2 (ja) * | 2014-01-17 | 2020-06-03 | オンコラル ファーマ エーピーエス | 癌治療のためのイリノテカンの固体経口剤形 |
| CN110448533B (zh) * | 2014-12-05 | 2022-03-29 | 天津键凯科技有限公司 | 一种聚乙二醇修饰的喜树碱类衍生物的药物组合物及其制备方法 |
| KR102293907B1 (ko) | 2015-06-30 | 2021-08-26 | 한미약품 주식회사 | 이리노테칸 함유 경구용 고형제제 및 그 제조방법 |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| KR102066402B1 (ko) * | 2017-12-22 | 2020-01-15 | 대화제약 주식회사 | 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물 |
| ES2949871T3 (es) | 2019-04-11 | 2023-10-03 | Janssen Pharmaceutica Nv | Anillos de piridina que contienen derivados como inhibidores de MALT1 |
| KR102185475B1 (ko) | 2019-06-20 | 2020-12-02 | 대화제약 주식회사 | 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ236393A (en) * | 1989-12-13 | 1992-05-26 | Lilly Co Eli | N-alkylated glycopeptide derivatives prepared from antibiotics a82846 series and pa-42867-a; pharmaceutical compositions |
| US5552156A (en) | 1992-10-23 | 1996-09-03 | Ohio State University | Liposomal and micellular stabilization of camptothecin drugs |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| US5433951A (en) | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
| IL115099A (en) * | 1994-10-14 | 1999-04-11 | Upjohn Co | Lyophilizate of phospholipid complex of water insoluble camptothecins |
| IL116674A (en) * | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| US5954998A (en) * | 1995-05-25 | 1999-09-21 | The Clorox Company | Liquid peracid precursor colloidal dispersions: oil-core vesicles |
| WO1998038984A2 (en) * | 1997-03-05 | 1998-09-11 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
| GB9711962D0 (en) * | 1997-06-10 | 1997-08-06 | Reckitt & Colmann Prod Ltd | Therapeutically active compositions |
| BR9810866B1 (pt) * | 1997-07-29 | 2010-07-13 | composição farmacêutica em uma forma de formulação auto-emulsificante para compostos lipofìlicos. | |
| AR013261A1 (es) * | 1997-08-01 | 2000-12-13 | Smithkline Beecham Corp | Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina |
| FR2775188B1 (fr) | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| EP1178795A1 (en) * | 1999-05-17 | 2002-02-13 | Ilex Oncology, Inc. | Dfmo and celecoxib in combination for cancer chemoprevention and therapy |
| GB9918885D0 (en) * | 1999-08-10 | 1999-10-13 | Pharmacia & Upjohn Spa | Pharmaceutical formulations in hydroxypropymethycellulose capsules |
-
1999
- 1999-10-22 GB GBGB9925127.4A patent/GB9925127D0/en not_active Ceased
-
2000
- 2000-10-02 IL IL14904400A patent/IL149044A0/xx active IP Right Grant
- 2000-10-02 HK HK03100370.7A patent/HK1048253B/zh not_active IP Right Cessation
- 2000-10-02 NZ NZ518398A patent/NZ518398A/en unknown
- 2000-10-02 EA EA200200480A patent/EA008284B1/ru not_active IP Right Cessation
- 2000-10-02 BR BR0014902-0A patent/BR0014902A/pt not_active Application Discontinuation
- 2000-10-02 MX MXPA02003904A patent/MXPA02003904A/es active IP Right Grant
- 2000-10-02 JP JP2001532771A patent/JP2003512430A/ja not_active Withdrawn
- 2000-10-02 US US10/110,225 patent/US7201913B1/en not_active Expired - Fee Related
- 2000-10-02 HU HU0202850A patent/HUP0202850A3/hu unknown
- 2000-10-02 PL PL00356236A patent/PL356236A1/xx not_active IP Right Cessation
- 2000-10-02 SK SK510-2002A patent/SK5102002A3/sk unknown
- 2000-10-02 KR KR1020027005068A patent/KR100838097B1/ko not_active Expired - Fee Related
- 2000-10-02 AU AU76613/00A patent/AU784201B2/en not_active Ceased
- 2000-10-02 CZ CZ20021372A patent/CZ20021372A3/cs unknown
- 2000-10-02 WO PCT/EP2000/009647 patent/WO2001030351A1/en not_active Ceased
- 2000-10-02 CA CA002387648A patent/CA2387648A1/en not_active Abandoned
- 2000-10-02 CN CNB008146594A patent/CN1198616C/zh not_active Expired - Fee Related
- 2000-10-02 EP EP00966102A patent/EP1223936A1/en not_active Withdrawn
- 2000-10-07 TW TW089121016A patent/TWI233355B/zh not_active IP Right Cessation
- 2000-10-19 AR ARP000105495A patent/AR031834A1/es unknown
- 2000-10-19 PE PE2000001113A patent/PE20010809A1/es not_active Application Discontinuation
- 2000-10-19 CO CO00079673A patent/CO5251471A1/es not_active Application Discontinuation
- 2000-10-19 MY MYPI20004934A patent/MY138106A/en unknown
-
2002
- 2002-04-09 IL IL149044A patent/IL149044A/en not_active IP Right Cessation
- 2002-04-17 ZA ZA200203042A patent/ZA200203042B/en unknown
- 2002-04-18 NO NO20021834A patent/NO322782B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL149044A (en) | 2007-03-08 |
| EP1223936A1 (en) | 2002-07-24 |
| BR0014902A (pt) | 2002-06-11 |
| JP2003512430A (ja) | 2003-04-02 |
| MXPA02003904A (es) | 2003-07-14 |
| HUP0202850A2 (hu) | 2003-01-28 |
| PE20010809A1 (es) | 2001-08-01 |
| KR100838097B1 (ko) | 2008-06-13 |
| NO20021834L (no) | 2002-04-18 |
| WO2001030351A1 (en) | 2001-05-03 |
| CN1198616C (zh) | 2005-04-27 |
| CA2387648A1 (en) | 2001-05-03 |
| CN1382050A (zh) | 2002-11-27 |
| SK5102002A3 (en) | 2002-11-06 |
| HK1048253B (zh) | 2005-12-02 |
| CO5251471A1 (es) | 2003-02-28 |
| HK1048253A1 (en) | 2003-03-28 |
| CZ20021372A3 (cs) | 2002-09-11 |
| AU784201B2 (en) | 2006-02-23 |
| KR20020045613A (ko) | 2002-06-19 |
| NO322782B1 (no) | 2006-12-11 |
| HUP0202850A3 (en) | 2004-12-28 |
| MY138106A (en) | 2009-04-30 |
| EA200200480A1 (ru) | 2002-10-31 |
| PL356236A1 (en) | 2004-06-28 |
| NZ518398A (en) | 2004-01-30 |
| GB9925127D0 (en) | 1999-12-22 |
| US7201913B1 (en) | 2007-04-10 |
| ZA200203042B (en) | 2003-04-17 |
| AU7661300A (en) | 2001-05-08 |
| EA008284B1 (ru) | 2007-04-27 |
| TWI233355B (en) | 2005-06-01 |
| NO20021834D0 (no) | 2002-04-18 |
| IL149044A0 (en) | 2002-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031834A1 (es) | Una composicion farmaceutica adecuada para su administracion por via oral, procedimientos para prepararla, una formulacion oral que la comprende, uso de un derivado de la camptotecina, un glicerido poliglicolizado y de un excipiente farmaceuticamente aceptable seleccionado entre lecitina, un fosfoli | |
| KR102500181B1 (ko) | 암-표적화 약물 운송수단으로서의 인지질 에테르 유사체 | |
| NO863620D0 (no) | Fremgangsmaate for fremstilling av et farmasoeytisk preparat | |
| ES2244098T3 (es) | Un conjugado covalente de clozapina con un acido graso y su uso para tratar la esquizofrenia. | |
| WO2004035032A3 (en) | Pharmaceutical formulations of camptothecine derivatives | |
| ES2564936T3 (es) | Aerosol nasal líquido que contiene naltrexona a dosis baja | |
| AR029084A1 (es) | Composiciones y metodos para el tratamiento del cancer | |
| DK0491778T3 (da) | Indretning til administration af medikamenter til slimhindevæv. | |
| ES2255287T3 (es) | Composiciones para el tratamiento de la leucemia linfocitica cronica. | |
| DE69531701D1 (de) | Sphingosome mit verbesserter arzneistoffabgage | |
| ES2090395T3 (es) | Formulados farmaceuticos gastroresistentes para administracion por via oral que contienen acidos biliares. | |
| ES2727686T3 (es) | Tratamiento de enfermedades que implican mucina | |
| BR0010082A (pt) | Método para melhorar a eficácia de um agente antitumoral | |
| AR018166A1 (es) | Productos utilizables en el tratamiento de tumores, una composicion farmaceutica y el uso de una antraciclina sola o con un inhibidor de topoisomerasa iantineoplasico en la preparacion de medicamentos | |
| AR043071A1 (es) | Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica | |
| AR057378A1 (es) | Formulaciones de diclofenac y metodos para usarlas | |
| PE20010407A1 (es) | Formulacion farmaceutica en capsulas de hidroxipropilmetilcelulosa | |
| ES2326825T3 (es) | Doxorubicina liposomal pegilada en combinacion con ecteinascidina 743. | |
| KR20100031759A (ko) | 흑색종의 치료 | |
| ES2243328T7 (es) | Preparado farmaceutico que contiene agentes citostaticos y aceptores de electrones para tratar cancer. | |
| AR014640A1 (es) | UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE. | |
| ES2215307T3 (es) | Composiciones con accion sinergica para combatir selectivamente tejidos tumorales. | |
| JPS624224A (ja) | 鎮痛剤、解熱剤または抗炎症剤を含む坐剤 | |
| AR025549A1 (es) | Mofetil micofelonato en asociacion con peg-ifn-alfa | |
| CN107519130A (zh) | 含有奎宁盐悬浊液的用于抗癌治疗的局部用药注射剂组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |